Robert Wittenberg

Advertising, Promotion, & Labeling; Social Media in Pharma/Device World. Policy Wonk. FDA OPDP (né DDMAC), APLB, CDRH Office of Compliance DPLC, HEOR

[Robert Wittenberg @PharmerRob]

FDA issues untitled letter after finding ‘eye-catching graphics’ in promotional emails https://t.co/xxvB79MFE9

[Robert Wittenberg @PharmerRob]

BeOne Medicines’ Brukinsa TV ad 'Clarity' hit by FDA over 'misleading suggestions' https://t.co/FFDLHZemso

[Robert Wittenberg @PharmerRob]

Insulet CEO details ‘Scrubs’ device promotion win as it boosts awareness, education drive https://t.co/gDrTG15CLh

[Robert Wittenberg @PharmerRob]

Alnylam rebuked by FDA over efficacy claims on Amvuttra website https://t.co/FcF3qL7zoO

[Robert Wittenberg @PharmerRob]

Bayer earns FDA untitled letter for Nubeqa's 'attention-grabbing visuals' https://t.co/OWsqgzenQw

[Robert Wittenberg @PharmerRob]

From Former # OPDP Researchers: Clinicians’ Reactions to Point-of-Care Advertising in Electronic Health Records https://t.co/V8wSQDrOp2

[Robert Wittenberg @PharmerRob]

AMA calls for regulatory crackdown on chatbots, wellness AI https://t.co/W4W2Qc0vUn via @statnews

[Robert Wittenberg @PharmerRob]

Drug ads face new scrutiny at FDA and on Hill https://t.co/e5wGB1iju3

[Robert Wittenberg @PharmerRob]

Pfizer rebuked by FDA for misleading Adcetris ads on Facebook https://t.co/ggsssRoyoB

[Robert Wittenberg @PharmerRob]

Does FDA Untitled Letter For Adcetris Facebook Ads Signal Start Of Social Media Crackdown? https://t.co/ZU4SPtbDBv

[Robert Wittenberg @PharmerRob]

ImmunityBio responds to FDA scrutiny over Anktiva promotional claims with new protocols https://t.co/jcGQzS0z2a

[Robert Wittenberg @PharmerRob]

FDA seeks legislative teeth to bite back against misleading DTC drug ads https://t.co/IwjtjK17Dg

[Robert Wittenberg @PharmerRob]

BMS, Novartis, Gilead, Iovance dinged over biologics promos in rare spate of CBER untitled letters https://t.co/Lag4lRy6rU

[Robert Wittenberg @PharmerRob]

Over-the-top psychedelic promos could undermine the field’s drug development efforts https://t.co/vzGRaYFC1F via @statnews

[Robert Wittenberg @PharmerRob]

How pharma marketers can capitalize on HCPs’ AI, social media and streaming habits https://t.co/ILCglDLAJW

[Robert Wittenberg @PharmerRob]

You Oughta Know: Companies Should Pay Attention When OPDP Drops a Warning Letter https://t.co/YXFvos8kmH

[Robert Wittenberg @PharmerRob]

Health influencers talk social media and mental health https://t.co/tiV11XapkX via @statnews

[Robert Wittenberg @PharmerRob]

ImmunityBio hit with FDA warning letter over Anktiva promotions in TV ad, podcast episode https://t.co/5Slrw9J78S

[Robert Wittenberg @PharmerRob]

A Maryland legislator wants pharma and patient groups to disclose ties to disease awareness campaigns https://t.co/Fn8rMZGpc0 via @statnews

[Robert Wittenberg @PharmerRob]

US FDA Snares Ozempic, Tremfya DTC Ads For Overstating Efficacy, GLP-1 Crackdown Continues https://t.co/D0CS7w7AMW